Sugi Predict

Sugi Predict / Compounds / SCHEMBL122587

SCHEMBL122587

SCHEMBL122587

Cc1c(C(=O)O)sc2ccc(Cl)cc12

nearest known ligand 0.58

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
▸ GPR35 Q9HC97 1/20 0.58
▸ MCL1 Q07820 5/20 0.57
▸ RXFP1 Q9HBX9 3/20 0.57
▸ BCKDK O14874 2/20 0.57
▸ PFKFB3 Q16875 2/20 0.50
▸ PFKFB4 Q16877 2/20 0.50
▸ BCL2L1 Q07817 2/20 0.50
▸ MAPT P10636 1/20 0.50
▸ TBXAS1 P24557 1/20 0.49
▸ ROCK1 Q13464 1/20 0.48
▸ NPSR1 Q6W5P4 2/20 0.47
▸ PKM P14618 1/20 0.47
▸ L3MBTL1 Q9Y468 1/20 0.45
▸ BCL2 P10415 1/20 0.44
▸ BAD Q92934 1/20 0.44
▸ CMA1 P23946 1/20 0.44
▸ PRNP P04156 1/20 0.44
▸ F10 P00742 1/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL121696 0.87 MAPT (0.50) GPR35MCL1RXFP1BCKDKPFKFB3
SCHEMBL121489 0.87 MAPT (0.50) GPR35MCL1RXFP1BCKDKPFKFB3
SCHEMBL12153769 0.87 MCL1 (0.71) GPR35MCL1RXFP1BCKDKBCL2L1
SCHEMBL2895952 0.83 GPR35 (0.62) GPR35MCL1RXFP1BCKDKBCL2L1
SCHEMBL5845473 0.83 MAPT (0.50) MCL1RXFP1BCKDKPFKFB3PFKFB4
SCHEMBL3318210 0.81 MAPT (0.49) GPR35MCL1RXFP1BCKDKPFKFB3
SCHEMBL3133584 0.81 OGG1 (0.52) PFKFB3PFKFB4MAPTROCK1NPSR1
SCHEMBL9757077 0.81 GPR35 (0.65) GPR35MCL1RXFP1BCKDKBCL2L1
SCHEMBL6659125 0.80 MAPT (0.49) MCL1RXFP1PFKFB3PFKFB4MAPT
SCHEMBL6958000 0.80 MAPT (0.48) GPR35MCL1RXFP1BCKDKPFKFB3

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 66 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20250346575-A1 ISOINDOLINONE DERIVATIVE HAVING GLUTARIMIDE MOTHER NUCLEUS, AND USE THEREOF KOREA RESEARCH INSTITUTE OF CHEMICAL TECHNOLOGY (KR) 2025-11-13 — — US disclosed
EP-4431505-A1 ISOINDOLINONE DERIVATIVE HAVING GLUTARIMIDE MOTHER NUCLEUS, AND USE THEREOF Korea Research Institute of Chemical Technology (KR) 2024-09-18 — — EP disclosed
CN-118234721-A Isoindolinone derivative with glutarimide mother nucleus and application thereof 韩国化学研究院 2024-06-21 — — CN disclosed
WO-2023085785-A1 ISOINDOLINONE DERIVATIVE HAVING GLUTARIMIDE MOTHER NUCLEUS, AND USE THEREOF 한국화학연구원 2023-05-19 — — WO disclosed
US-8962607-B2 Azetidinyl diamides as monoacylglycerol lipase inhibitors JANSSEN PHARMACEUTICA NV (BE) 2015-02-24 — — US disclosed
US-8759533-B2 Di-azetidinyl diamide as monoacylglcerol lipase inhibitors JANSSEN PHARMACEUTICA NV (BE) 2014-06-24 — — US disclosed
US-8759333-B2 Di-azetidinyl diamide as monoacylglycerol lipase inhibitors JANSSEN PHARMACEUTICA NV (BE) 2014-06-24 — — US disclosed
US-8748417-B2 Amino-pyrrolidine-azetidine diamides as monoacylglycerol lipase inhibitors JANSSEN PHARMACEUTICA N.V. (BE) 2014-06-10 — — US disclosed
US-8748417-B2 Amino-pyrrolidine-azetidine diamides as monoacylglycerol lipase inhibitors JANSSEN PHARMACEUTICA N.V. (BE) 2014-06-10 — — US disclosed
US-8722658-B2 Azetidinyl diamides as monoacylglycerol lipase inhibitors JANSSEN PHARMACEUTICA NV (BE) 2014-05-13 — — US disclosed
US-20080039442-A1 Compounds With Kv4 Ion Channel Activity DEVGEN NV (BE) 2008-02-14 — — US disclosed
US-20070259965-A1 Acyclic 1,3-Diamine And Uses Therefor SMITHKLINE BEECHAM CORPORATION 2007-11-08 — — US disclosed
EP-1847532-A1 IGF-1R INHIBITOR KYOWA HAKKO KOGYO CO., LTD. (JP) 2007-10-24 — — EP disclosed
EP-1838690-A2 COMPOUNDS WITH KV4 ION CHANNEL ACTIVITY Devgen N.V. (BE) 2007-10-03 — — EP disclosed
EP-1797065-A2 ACYCLIC 1,3-DIAMINES AND USES THEREFOR SMITHKLINE BEECHAM CORPORATION (US) 2007-06-20 — — EP disclosed
US-20070082907-A1 Peroxisome proliferator activated receptor modulators ELI LILLY AND COMPANY (IN) 2007-04-12 — — US disclosed
EP-1697304-A1 PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR MODULATORS ELI LILLY AND COMPANY (US) 2006-09-06 — — EP disclosed
WO-2006066879-A2 COMPOUNDS WITH KV4 ION CHANNEL ACTIVITY DEVGEN N.V. (BE) 2006-06-29 — — WO disclosed
WO-2006029210-A2 ACYCLIC 1,3-DIAMINES AND USES THEREFOR SMITHKLINE BEECHAM CORPORATION (US) 2006-03-16 — — WO disclosed
WO-2005054176-A1 PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR MODULATORS ELI LILLY AND COMPANY (US) 2005-06-16 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080039442-A1 Compounds With Kv4 Ion Channel Activity KCNA4, HCN4, KCNN4 GPR35 924/4885MCL1 3701/4885RXFP1 532/4885
US-20070259965-A1 Acyclic 1,3-Diamine And Uses Therefor TRPV4, TRPC4, TRPV1 GPR35 176/4885MCL1 4289/4885RXFP1 157/4885
US-20070082907-A1 Peroxisome proliferator activated receptor modulators PPARG, PPARA, PPARD GPR35 166/4885MCL1 4564/4885RXFP1 896/4885
US-20250346575-A1 ISOINDOLINONE DERIVATIVE HAVING GLUTARIMIDE MOTHER NUCLEUS, AND USE THEREOF CRBN, IDH1, IDH2 GPR35 1252/4885MCL1 121/4885RXFP1 4212/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.